Review Article

Therapeutic Effects of Polyphenols on the Treatment of Colorectal Cancer by Regulating Wnt β-Catenin Signaling Pathway

Mehran Pashirzad,1 Thomas P. Johnston,2 and Amirhossein Sahebkar3,4,5

1Department of Medical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, USA
3Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
4Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
5School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Correspondence should be addressed to Amirhossein Sahebkar; amir_saheb2000@yahoo.com

Received 17 July 2021; Accepted 17 September 2021; Published 28 September 2021

Academic Editor: Ashok Pandurangan

Copyright © 2021 Mehran Pashirzad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Colorectal cancer (CRC) is the third most common cause of cancer-related death worldwide in terms of both its rates of incidence and mortality. Due to serious side effects associated with conventional chemotherapeutic treatments, many natural products with fewer adverse side effects have been considered as potential treatment options. In fact, many natural products have widely been used in various phases of clinical trials for CRC, as well as in in vitro and in vivo preclinical studies. Curcumin (CUR) and resveratrol (RES) are classified as natural polyphenolic compounds that have been demonstrated to have anticancer activity against CRC and are associated with minimal side effects. By regulating select target genes involved in several key signaling pathways in CRC, in particular, the Wnt β-catenin signaling cascade, the course of CRC may be positively altered. In the current review, we focused on the therapeutic effects of CUR and RES in CRC as they pertain to modulation of the Wnt β-catenin signaling pathway.

1. Introduction

Colorectal cancer (CRC) is the third most common cause of cancer-related death worldwide in terms of both its rates of incidence and mortality, which are increasing every year [1]. There are various conventional therapies for the treatment of patients with CRC, which include surgery, radiotherapy, and chemotherapy. All of these treatment modalities have severe side effects such as drug toxicity, drug resistance, and hepatic injury [2, 3]. Thus, in view of the increased side effects with conventional treatment methods, there has been increased interest to identify novel and effective therapies with fewer side effects for treating patients with CRC [4]. Based on recent findings concerning CRC treatment, many natural compounds have been extensively studied and used in various phases of clinical trials, as well as in in vitro and in vivo preclinical studies [5, 6].

Curcumin (CUR) is a natural product derived from the rhizome of Curcuma longa with proven efficacy to treat a number of diseases and exhibiting minimal side effects [7, 8]. This polyphenolic compound exhibits numerous pharmacological properties against a variety of pathological conditions [9–17]. In addition, it has been shown that CUR can inhibit many molecular signaling pathways, in particular, the Wnt β-catenin signaling pathway, which is associated with its anticancer effects in a variety of human CRC cell lines [14, 18].

Resveratrol (RES) is also a polyphenolic compound and is extracted from many plants such as grapes, peanuts, and berries [19]. RES has proven chemopreventive properties and can influence the pathogenesis of many diseases though with conflicting results [20–23]. It is known that the therapeutic properties of RES are associated with its anti-inflammatory, antiangiogenic, and antioxidant effects [24, 25]. Recent results of several studies have shown that RES can target several
molecular signaling pathways, including the Wnt β-catenin signaling pathway, and inhibit cell proliferation and induce apoptosis in many solid tumors such as CRC [25, 26].

Wnt signaling is the most common pathway involved in the regulation of the cell cycle, stemness, and cancer [27]. Wnt signaling represents one of the initial key signaling cascades involved in CRC recurrence. Moreover, there exists a strong relationship between the inhibition of this pathway and the exposure of cancer cells to CUR and RES [28, 29]. In this review, we summarize the underlying mechanisms of the antitumor activity of CUR and RES via inhibition of the Wnt β-catenin signaling pathway in tumorigenesis and the recurrence of CRC.

2. Wnt β-Catenin Signaling Pathway

The Wnt signaling pathway can generally be divided into canonical Wnt β-catenin signaling and noncanonical Wnt signaling [30]. In the present review, the role of Wnt β-catenin signaling in CRC is discussed. The regulation of cellular processes induced by Wnt β-catenin signaling is associated with the presence, or absence, of Wnt ligands, which are known to be secreted glycoproteins [31]. In the absence of Wnt proteins, the β-catenin destruction complex is derived from intracellular molecular signals including adenomatous polyposis coli (APC), Axin (a scaffolding protein controlling β-catenin stability), glycogen synthase kinase 3β (GSK3β), and casein kinase 1α (CK1α) [32]. Following the formation of the β-catenin destruction complex, phosphorylation and ubiquitination of β-catenin are mediated by GSK3β and β-transducin repeat-containing protein (β-TrCP), with eventual translocation of β-catenin into the cell nucleus and inhibition in the expression of target genes involved in regulating cellular processes [33]. In contrast to the inactivation of the Wnt β-catenin pathway, canonical Wnt signaling is characterized by binding of Wnt proteins to Frizzled receptors (Fzd) and low-density lipoprotein receptor-related protein 5/6 (LRP5/6), phosphorylation of Disheveled (Dvl), inhibition of the β-catenin destruction complex, translocation of β-catenin into the nucleus, and β-catenin and T-cell factor/lymphocyte enhancer factor (TCF/LEF) induced overexpression of target genes such as cyclin D1 and c-Myc, respectively [34].

In a state of homeostasis, Wnt β-catenin signaling pathway plays an important role in regulating the cell cycle, as well as the growth, proliferation, and differentiation of cells [35]. In contrast to the homeostatic state, aberrant activation of canonical Wnt β-catenin signaling induced by genetic/epigenetic disorders promotes proliferation and tumor growth of cancer cells, in particular, CRC cells [36]. The dysregulation in Wnt β-catenin signaling can be inhibited by antibodies [37], shRNA molecules [38], Wnt signaling inhibitors [39], and an impressive number of natural compounds during CRC progression [40].

2.1. Wnt β-Catenin Signaling and CRC. Epithelial cells of the colon and small intestine normally comprise the functional unit termed the crypt, which includes the crypt base, transit-amplifying cells, and terminally differentiated cells [41]. The crypt base region contains different cells, including Paneth cells and crypt base columnar cells (CBCs). Their cellular processes include proliferation, differentiation, and apoptosis, which are significantly dependent on the activation of Wnt β-catenin transduction [42]. In contrast, there are a wide range of genetic and epigenetic changes involved in the progression of CRC, which are closely associated with mutations and dysregulation of the Wnt β-catenin signaling components, such as APC and β-catenin proteins located at the crypt base of the colonic epithelium [43]. Although Wnt β-catenin signaling is considered the initial pathway involved in the early stages of CRC, it also plays an important role in regulating gene expression and several cellular processes. For example, these cellular processes include invasion, proliferation, migration, differentiation, and apoptosis from the time of initiation to the time of recurrence of CRC [44]. On the other hand, it has been determined that the development of APC and β-catenin mutation-induced overactivation of Wnt β-catenin signaling also occurs in the early stages of CRC [45]. Along these lines, mutation and dysregulation of APC trigger the accumulation of cytoplasmic β-catenin, translocation of the β-catenin into the nucleus, and overexpression of genes associated with the progression of CRC [45]. An increase in the expression levels of genes of the Wnt β-catenin cascade involved in CRC, which include c-Myc [46], Cyclin D1 [47], matrix metalloproteins (MMPs) [48], and Musashi1 (Msi1) [49], results in the activation of aberrant Wnt β-catenin signaling in colonic epithelial cells and subsequent development and progression of CRC. Many of the biological and pharmacological factors normally thought of as Wnt antagonists, can affect disturbed regulation of Wnt β-catenin signaling, and can be considered as potential therapeutic agents for various types of colon cancer.

2.2. Components of Wnt β-Catenin Signaling as Therapeutic Targets for CRC. Due to the rate of recurrence of cancer in patients with CRC, therapeutic treatment methods such as biotherapy, radiotherapy, surgery, and curative antibodies in combination with conventional chemotherapy are used [50]. Regarding recent clinical trials targeting different stages of CRC, combination therapy of Wnt antagonists with other therapeutic interventions, which include natural compounds [51], nonsteroidal anti-inflammatory drugs (NSAIDs) [52], and biological inhibitors [53], is currently considered an effective treatment strategy for CRC. Two such natural compounds that can effectively modulate impaired Wnt β-catenin signaling are CUR and RES. It has been shown that these natural compounds such as micronized resveratrol (SRT501; NCT00920803) [54], resveratrol-rich fresh red grapes [55], genistein (NCT01985763), quercetin (NCT00033063), and green tea (NCT0435978), in combination with chemotherapeutic agents including celecoxib (NCT00295035) [56], 5-fluorouracil (NCT02724202) [57], and irinotecan (NCT01859858) [58], can effectively target dysregulated components of Wnt β-catenin signaling associated with the progression of CRC.
The characteristics of various natural compounds, especially CUR and RES (i.e., two natural compounds that are the subject of this review), as they pertain to modulation of the Wnt β-catenin signaling at different stages of CRC, are summarized in Table 1. As mentioned above, this review discusses the inhibitory effects of polyphenolic natural products, with the primary focus on CUR and RES, in a wide variety of CRC cell lines.

2.3. Antitumor Activity of Curcumin Mediated by Wnt β-Catenin Signaling in Different Cellular Processes of CRC Cells. Based on the results of previous studies, curcumin inhibits aberrant activation of several signaling pathways including the Wnt β-catenin signaling pathway, which is activated by many tumorigenic factors such as azoxymethane (AOM), dextran sodium sulfate (DSS), and dibenzazepine (DBZ) as determined in various in vitro and in vivo studies [59, 60]. Regarding recent findings concerning CUR’s anticancer activity, this natural product can also inhibit different cellular processes, which include cell proliferation [61], apoptosis [62], cell viability [63], cell cycle dynamics [64], invasiveness [65], and metastasis [66] of various CRC cell lines.

2.4. Cell Proliferation. Using a mouse model in which CRC was induced via AOM and DSS, together with real-time quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry (IHC), Hao et al. have shown that CUR significantly suppresses tumor cell proliferation of colorectal tissue through the downregulation of interleukin-1β (IL-1β), IL-6, cyclooxygenase-2 (COX-2), β-catenin, and Axin-2, which was mediated by the inactivation of the Wnt β-catenin signaling pathway [64, 67]. In another study, the survival rate of CRC cells, including cell proliferation, was evaluated to determine the underlying mechanisms for CUR’s antiproliferative activity. SW480 and HCT116 cells were treated with CUR and exhibited the lowest viability, as well as loss of cell proliferation capabilities, which suggested that CUR inhibits cell proliferation of these cells by the inactivation of Wnt β-catenin signaling pathway. Specifically, it was suggested that the mechanism of inhibition of cell proliferation was Wnt β-catenin signaling-mediated overexpression of β-catenin, TCF4, microRNA-21 (miR-21), and miR-130a, in conjunction with downregulation of a negative regulator of this pathway (i.e., naked cuticle homolog 2 (Nkd2)) [68]. One of the most important microRNAs which is mostly downregulated in several cancers such as hepatocellular carcinoma and CRC is miR-491. This microRNA is also negatively associated with some of the mediators of Wnt β-catenin signaling including paternally expressed gene 10 (PEG10), SIAH1 gene, Wnt1, Wnt3a, and β-catenin [69, 70]. Since cell proliferation of CRC cells is inhibited via CUR-mediated suppression of Wnt β-catenin signaling, this natural product may also potentially target miR-491/PEG10 and regulate cell proliferation during CRC recurrence. Accordingly, Li et al. reported that CUR reduced cell proliferation and stimulated apoptosis of HCT116 cell lines by upregulating miR-491 and downregulating PEG10 and Wnt β-catenin signaling [71].

In addition to CUR, its chemical derivatives, which include demethoxycurcumin (DMC), bisdemethoxycurcumin (BDMC), and tetrahydrocurcumin (THC), are able to inhibit cell proliferation of various cancer cell lines via inactivation of Wnt β-catenin signaling [72, 73]. In line with these findings, another study investigated the potential of CUR and its derivatives to inactivate Wnt β-catenin-induced aberrant cell proliferation of CRC cells. This study employed transfection of Wnt3a-conditioned medium (CM) treated HEK293 reporter (SEAP) cell lines into plasmid expressing hFz-1. Based on the activity of firefly luciferase (FL), it was demonstrated that CUR and its analogs inhibit cell proliferation of several CRC cell lines (e.g., HCT116, SW480, HCT15, and DLD-1) by decreasing FL and SEAP activity induced by Wnt3a-CM, reducing the expression and degradation of cytoplasmic β-catenin, and downregulating a positive regulator of this signaling pathway called p-300 activator [74]. In contrast to the anti-proliferative effects of CUR during CRC development, it has been shown that its derivative (THC) more effectively inhibits cell proliferation of various cancer cell lines when compared to CUR [75, 76]. Along these lines, analyses using IHC and western blotting in an AOM-induced colon carcinogenesis animal model showed that THC, in a concentration-dependent manner, could dramatically inhibit colonic epithelial cell proliferation when compared to CUR. These same authors proposed that THC’s activity was achieved by reducing the expression levels of β-catenin, Wnt1, and GSK3β, which suggests that dietary consumption of THC may potentially decrease the number of aberrant crypt foci (ACF) [77].

In addition to the antitumor effects of CUR in CRC, this natural compound can effectively modulate drug resistance of some chemotherapy drugs (e.g., 5-fluorouracil (5-FU)) during the development of the epithelial-mesenchymal transition (EMT) [78]. One of the most effective factors for increasing drug resistance in many cancers is EMT, which is associated with changes in cell polarity and the destruction of cell membranes and extracellular matrix [79]. In further support of CUR decreasing drug resistance of 5-FU during EMT, it has been demonstrated that following the addition of CUR to HCT116 cells, 5-FU-treated HCT116 cell lines show less proliferation, increased apoptosis, and suppression of the G0/G1 phase. These effects were suggested to occur due to a Wnt β-catenin signaling-mediated loss in the expression of tumor suppressor genes, including ten-eleven translocation 1 (TET1) and Nkd2, as well as an upregulation of β-catenin, TCF4, and Axin [80]. Importantly, as discussed below, CUR has also been evaluated in combination with other natural compounds to inhibit cancer cell proliferation.

Since CUR can potentially strengthen the inhibitory effects of 5-FU during EMT, it is possible that CUR may also synergistically augment the antitumor effects of the natural compound quercetin during EMT and thereby suppress the proliferation of CRC cells. Specifically, a previous study reported that the combination of CUR and quercetin synergistically inhibited the proliferation of HCT116 cells in a...
In a previous study, folate-conjugated polymeric micelles were a promising candidate for colon cancer via the inhibition of the Wnt β-catenin signaling pathway [86].

### 2.5. Apoptosis and the Cell Cycle

In contrast to the anti-proliferative activity of CUR in regulating the proliferation of CRC cells, it has been reported that CUR also increases apoptosis and reduces cell viability. It has been suggested that CUR mediates increased apoptosis and reduced cell viability by decreasing the expression levels of β-catenin in the cell cytoplasm and nucleus. They concluded that the anticancer effects of FA-Cur micelles were a promising candidate for colon cancer via the inhibition of the Wnt β-catenin signaling pathway [86].

| Natural compounds | Interventions | Target | Phase | Dose | Duration | NCT number | Reference |
|-------------------|---------------|--------|-------|------|----------|------------|-----------|
| Curcumin          | Celecoxib 5-Fluorouracil, Irinotecan | TCF/β-catenin | III   | N.M | N.M | N.M N.M | NCT00295035 NCT02724202 [56] |
|                   | Oral curcumin (1,2,3, or 4 g/day) for 4 days + 200 mg/m² irinotecan IV | | 1       | N.M | N.M | June 2013–October 2016 | NCT01859858 [58] |
| Resveratrol       | SRT501        | PDE4   | I     | 5.0 g oral administration of SRT501 | August 2008–November 2009 | NCT00920803 [54] |
| Genistein         | mFOLFOX/mFOLFOX + Avastin | GSK3β | I/I   | Combination genistein with mFOLFOX/mFOLFOX + Avastin (60 mg/day orally for 7 days every 2 weeks) | November 2013–October 2018 | NCT01985763 — |
| Quercetin         | Curcumin/rutin/quercetin/sulindac | —     | Clinical | Oral sulindac (twice a day), oral rutin (1 of 3 doses twice a day), oral quercetin (1 of 3 doses twice a day), and oral curcumin (1 of 3 doses twice a day) | August 1996–July 2006 | NCT00003365 — |
| Green tea         | Fasting       | —     | Clinical | — | 8 hours before CRC surgery and 8 hours after CRC surgery | January 2020–September 2023 | NCT04345978 — |
|                   | GTE (green tea extract) | —     | Clinical | 0.9 g/day (GTE) and 0.6 g/day (EGCG) | August 2010–October 2015 | NCT02321969 — |

Table 1: Therapeutic effects of some natural compounds on CRC in different stages of clinical trials.
effects of CUR on CRC cells, it can also effectively reduce various cellular processes of cancer stem cells (CSCs). It is thought that CUR affects cellular processes of CSCs by targeting several signaling pathways that modulate the expression of select genes, which would seem to suggest that CUR may potentially target CSCs in many kinds of human cancers [89, 90]. Additionally, during the formation of CRC stem cells (CRC-SCs) and the development of increased drug resistance, it has been reported that CUR can also attenuate drug resistance to other chemotherapeutic drugs such as irinotecan (CPT-11), which is thought to be mediated by inhibition of several signaling pathways that affect the establishment and proliferation of CRC-SCs. Based on the positive relationship between CUR and CPT-11, as it pertains to drug resistance exhibited by CRC-SCs, another study demonstrated that CUR can significantly decrease drug resistance of LoVo-CPT-11 cells, inhibit features of CRC-SCs needed for sphere formation, and finally, stimulate apoptosis of sphere-forming cells. The effects of CUR on LoVo-CPT-11 cells were suggested to occur due to a reduction in the expression levels of various markers of CRC-SCs, which include the cluster of differentiation (CD) markers such as CD24, CD133, and CD44, as well as epithelial cell adhesion molecule (EpCAM) [91].

2.6. Metastasis and Invasion. In a study by Zhang et al. curcumin was evaluated for its potential to inhibit tumor EMT through the Wnt signaling pathway in colon cancer cells. Naked cuticle homolog 2 (Nkd2) small-interfering RNA (siRNA) and chemokine receptor 4 (CXCR4) expression plasmid were synthesized and transfected into curcumin-treated SW620 colorectal cancer cell lines, and the NKD2 and CXCR4 expression levels were determined. Their findings showed that curcumin significantly inhibited the proliferation of colorectal cancer cells and upregulated the expression of NKD2 in the cells, which resulted in the downregulation of key markers in Wnt signaling. Moreover, the progression of EMT was inhibited due to an overexpression of E-cadherin and downregulation of vimentin, as well as inhibition in tumor metastasis due to a significant downregulation in the expression of CXCR4 [92]. In addition to CUR’s anticancer activity in metastasis and invasion of CRC cells, the combination of CUR with siRNAs to mediate restoration in the overexpression of select target genes may also potentially inhibit metastasis and invasiveness of CRC cells [93]. Along these lines, findings from a previous study demonstrated that combination of CUR with an siRNA targeting metastasis-associated lung adenocarcinoma transcript1 (si-MALAT1) can significantly suppress the migration and invasion of SW480 cells via downregulation in the expression levels of c-Myc, ββ-catenin, and cyclin D1, which is mediated by inactivation of the Wnt ββ-catenin cascade. This would suggest that si-MALAT1 can potentially increase the sensitivity of SW480 cells to CUR [93].

One of the most effective pathological processes for increasing the malignant nature of CRC is EMT, which plays a crucial role in promoting metastasis and invasion of human CRC cells [94]. To enhance metastasis and invasion of CRC cells during the EMT process, downstream mediators of the Wnt ββ-catenin pathway are essential [95, 96]. Curcumin can also potentially target components of Wnt β-catenin signaling, which include target genes, β-catenin, and tumor suppressors in an effort to suppress EMT-induced metastasis and invasion of CRC cells [97]. In one study, CUR was evaluated for its inhibitory effects on EMT in CRC cells. Human SW480 cells were incubated with increasing concentrations of CUR. DNA methylation levels of the CDX2 promoter were assessed, as were mRNA levels using RT-qPCR, protein expression levels using Western blotting, and nuclear translocation of β-catenin using immunofluorescence. Incubation of the cells with varying concentrations of CUR significantly downregulated the expression levels of DNA methyltransferase1 (DNMT1) and the methylation levels of the CDX2 promoter in a concentration-dependent manner. In addition, the nuclear translocation levels of β-catenin were also reduced in a concentration-dependent manner. These authors concluded that CUR negatively regulated transcription factors promoting EMT in CRC cells by decreasing CDX2 promoter DNA methylation and consequently suppressing the CDX2/ Wnt3a/β-catenin signaling pathway [97].

In contrast with these results, the anti-inflammatory effects of CUR were evaluated by Ahmed et al. in an animal model of colitis induced by Citrobacter rodentium infection and were shown to promote cell survival and mucosal regeneration by restoring Wnt β-catenin signaling. These investigators used a mouse model wherein a C. rodentium infection induced transmissible murine colonic hyperplasia (TMCH) and various degrees of inflammation. Chronic administration of dibenzazepine (DBZ) for 10 days was utilized to block both Notch and Wnt signaling, disrupt the intestinal barrier, and induce colitis. Dietary curcumin (4%) restored signaling via Notch and Wnt/β-catenin pathways, which promoted crypt regeneration, replenishment of the mucus layer, and thus, an amelioration of the C. rodentium- and DBZ-induced colitis. Therefore, CUR inhibited TMCH and colitis induced with DBZ administration and C. rodentium infection in mice [98] (Table 2).

2.7. Anticancer Activity of Resveratrol Is Mediated by Wnt β-Catenin Signaling in Different Cellular Processes of CRC Cells. Based on the results of several previous studies, resveratrol can potentially target aberrant activation of several signaling pathways, including the Wnt β-catenin signaling pathway induced by various tumorigenic factors. Consequently, by inhibiting the Wnt β-catenin signaling pathway, resveratrol has been shown to affect several cellular processes of CRC cells such as cell proliferation, apoptosis, cell cycle dynamics, metastasis, and overall invasiveness.

2.8. Cell Proliferation. Resveratrol is known to inhibit cell proliferation and induce apoptosis in cancer cell lines at concentrations above 50 μM. However, its effects on Wnt signaling are still being investigated. One study by Hope et al. examined the effects of RES on cell proliferation and
Wnt signaling at low concentrations. Specifically, this study used two colon cancer cell lines (HT29 and RKO) and one normal mucosa-derived (NCM460) cell line. RES had no effect on cell proliferation at \( \leq 40 \mu M \) (HT29 and NCM460) and \( \leq 20 \mu M \) (RKO), although, at concentrations as low as 10 \( \mu M \), RES significantly decreased the amount and proportion of \( \beta \)-catenin in the nucleus of RKO and reduced the expression of lgs and pygol (regulators of \( \beta \)-catenin localization) in all cell lines. These authors concluded that at low concentrations in the absence of effects on cell proliferation, RES significantly inhibited Wnt signaling in colon-derived cancer cells, which appeared to be due in part to intracellular \( \beta \)-catenin localization \[99\]. Furthermore, RES can also target-specific signaling pathways involved in cell proliferation, which include the PI3K/Akt and Wnt \( \beta \)-catenin signaling pathways, to suppress cell proliferation of...
CRC cells [100]. In fact, it has been shown that RES significantly suppresses cell proliferation of HCT116 cells by upregulating PTEN, and decreasing Akt1/2. The exogenous expression of PTEN inhibits the PI3K/Akt signal and promotes the antiproliferative effects of RES in HCT116 cells, while knockdown of PTEN increases the PI3K/Akt signal and promotes the antiproliferative effects of RES in human colon cancer cells [100].

Resveratrol has also been evaluated to determine whether it can target the β-catenin/T-cell factor (TCF) complex in the β-catenin signaling pathway. Using co-immunoprecipitation, together with in vitro binding assays, Chen et al. demonstrated that RES was capable of disrupting the binding between β-catenin and TCF4, which contributes to a decrease in Wnt signaling and Wnt β-catenin-mediated aberrant cell proliferation. Based on these findings, it was shown that RES is capable of identifying, and ultimately destroying, the β-catenin-TCF4 complex to inhibit the growth of P19 and COS-7 CRC cell lines mediated by inactivation of Wnt β-catenin. This process was suggested to be due to downregulation in the expression of Wnt target genes such as cyclin D1, Axin2, ET-1, and c-Myc without altering the expression levels of cytoplasmic and nuclear β-catenin [101].

In contrast to the antiproliferative role of RES in Wnt β-catenin pathway-mediated cell proliferation, it was demonstrated using Wnt signaling-specific microarray analysis and RT-qPCR that low doses of RES-containing freeze-dried grape powder (GP) did not significantly inhibit the Wnt pathway in colon cancer but had significant activity in inhibiting Wnt target gene expression in normal colonic mucosa obtained from eight patients. However, the GP, which contains low dosages of RES in combination with other bioactive components, at 80 g/day can inhibit the Wnt pathway in vivo, and this effect appeared to be confined to normal colonic mucosa [102].

Although RES’s antiproliferative activity does not influence cell proliferation during CRC progression, it has been proven that RES can extensively target several mediators in CRC cells that are overexpressed (e.g., insulin growth factor1 (IGF-1)) and thereby suppress cell proliferation mediated by aberrant activation of Wnt β-catenin [103]. One of the most effective mediators for enhancing the antiproliferative effects of RES on the proliferation of CRC cells is IGF-1, which is highly expressed in the crypts of proliferating colonic cells during CRC progression [104]. In view of the significant negative relationship between RES and IGF-1, it has also been observed that RES can suppress cell proliferation of CRC cells by inhibiting IGF-1-induced aberrant activation of Akt/Wnt β-catenin signaling that mediates CRC cell growth [103]. Similar to IGF-1, prostaglandin E2 (PGE2) is highly expressed in CRC cells during tumorigenesis and is also considered a target for RES to effectuate inhibition of Wnt β-catenin signaling-mediated cell proliferation [105]. Indeed, it has been shown that RES can suppress cell proliferation and cell growth of PGE2-treated LS174T cells. It was proposed that the underlying mechanism responsible for this finding was inhibition of a PGE2-stimulated increase in downstream target genes of Wnt β-catenin, including the phosphorylation of GSK3β, the expression levels of cytoplasmic and nuclear β-catenin, and the expression levels of c-Myc and cyclin D1 [105].

### Table 3: Anticancer effects of resveratrol mediated by Wnt β-catenin signaling on CRC cells.

| Effect | Action mechanism | Resveratrol Mediators | Targeted therapy | Sample type | Reference |
|--------|------------------|----------------------|------------------|-------------|-----------|
| Antiproliferative | Inhibiting cell proliferation | Inhibiting PI3K/Akt/Wnt β-catenin signaling, upregulation of PTEN, and decreasing β-catenin expression | PI3K/Akt/Wnt β-catenin signaling | HCT116 | [100] |
| | Suppressing cell growth | Inactivation of Wnt β-catenin signaling and downregulation of cyclin D1, Axin2, ET-1, and c-Myc | TCF-β-catenin binding | P19 and COS-7 | [101] |
| | Inhibiting cell growth and cell proliferation | Suppressing IGF-1 | IGF-1 | HT-29 and SW480 | [103] |
| | Suppressing cell proliferation | Inhibiting PGE2 expression, downregulation of cyclin D1 and c-Myc, and decreasing GSK3β phosphorylation and β-catenin expression | PGE2 | LS174T | [105] |
| Apoptotic | Inducing apoptosis | Increasing p53 and COX-2 expression and low-expression of β-catenin and HMGA2 | Tetrac | HCT116 and HT-29 | [108] |
| | Stimulating apoptosis and inhibiting cell proliferation | Upregulation of p27 and p53, arresting G0/G1-S cell cycle phase, and low expression of cyclin D1 | IGF-1 | HT-29 and SW480 | [109] |
| | Increasing apoptosis | Enhancing proteolytic proteasomal degradation induced by TCF4, decreasing TCF4 and c-Myc expression, as well as reducing exogenous myc-tagged TCF4 | TCF-4 and c-Myc | LoVo and HCT116 | [110] |
2.9. Apoptosis and Cell Cycle. According to the findings of several recent studies, the antiproliferative and apoptotic effects of RES are mechanistically dependent on RES-bonded integrin αvβ3-induced activation of extracellular signal-regulated kinase-1 and kinase-2 (ERK1/2) and stimulation of COX-2 accumulation. Accordingly, apoptosis of various human cancer cells is ultimately induced via upregulation of target genes (e.g., p53) involved in apoptosis [106, 107].

There are several strategies to enhance the antiproliferative and apoptotic activity of RES during CRC development. For example, it has been reported that the combination of RES with tetraiodothyroacetic acid (tetrac), as an anticancer agent, leads to a synergistic augmentation in the antiproliferative and apoptotic effects of RES. It is thought that the combination of RES and tetrac to induce apoptosis of CRC cells is mediated by inhibiting Wnt β-catenin-induced overexpression of β-catenin and high mobility group protein A2 (HMGA2), as well as increasing both the nuclear accumulation of COX-2 and the expression levels of p53 [108]. In addition to RES promoting apoptosis mediated by ERK1/2 signaling, RES may also potentially target select regulators involved with Wnt β-catenin signaling disorder, such as IGF-1. This leads to suppression of cell proliferation and, ultimately, induces apoptosis of CRC cells. Along these lines, findings from a different study showed that following the addition of IGF-1 to HT-29 and SW480 cells, RES (100–150 μM) exhibited antiproliferative properties in the HT-29 cells even after IGF-1 exposure by arresting the G0/G1-S phase of cell cycle progression via p27 stimulation and cyclin D1 suppression [109]. These authors concluded that RES inhibits CRC cell proliferation and elevates apoptosis (even in the presence of IGF-1) by suppressing the IGF-1/ Akt/Wnt signaling pathway [74]. There are several effective factors, which include downstream target genes associated with Wnt β-catenin signaling (e.g., TCF-4 and c-Myc), that enhance the inhibitory effects of RES and induce RES-stimulated apoptosis [110]. In a study by Jeong et al., it was demonstrated that RES induced apoptosis of human CRC cell lines (including HCT116 and LoVo) in a dose and time-dependent manner by increasing the proteolytic proteasomal degradation of TCF4, reducing a downstream target of TCF4 (i.e., c-Myc), and decreasing exogenous Myc-tagged TCF4 without changing expression levels of β-catenin [110] (Table 3).

3. Conclusion

In this review, we have summarized recent findings on the antitumor effects of CUR and RES in the pathogenesis of CRC as it pertains to the Wnt β-catenin signaling pathway (Figure 1). CUR and RES can target many of the mediators that regulate cellular processes of CRC cells via Wnt β-catenin signaling, suggesting that these natural compounds may represent appropriate therapeutic agents for the treatment of CRC. However, to consider both CUR and RES as suitable therapeutic interventions for the treatment of CRC, it is essential that the mechanism(s) underlying their effects to regulate both downstream and/or upstream mediators in signaling pathways associated with CRC progression and recurrence is (are) more clearly elucidated.

Abbreviations

| Abbreviation | Meaning |
|--------------|---------|
| CRC          | Colorectal cancer |
| CUR          | Curcumin |
| RES          | Resveratrol |
| Wnt          | Wingless transduction |
| APC          | Adenomatous polyposis coli |
| GSK3β        | Glycogen synthase kinase 3β |
| CK1α         | Casein kinase 1α |
| β-TrCP       | β-Transducin repeat-containing protein |
| Fzd          | Frizzled receptor |
References

[1] J. A. Meyerhardt and R. J. Mayer, “Systemic therapy for colorectal cancer,” New England Journal of Medicine, vol. 352, no. 5, pp. 476–487, 2005.

[2] K. E. Wong, S. C. Ngai, K. G. Chan, L. H. Lee, B. H. Goh, and L. H. Chuaah, “Curcumin nanoformulations for colorectal cancer: a review,” Frontiers in Pharmacology, vol. 10, p. 152, 2019.

[3] N. A. Molodecky, S. Soon, D. M. Rabi et al., “Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review,” Gastroenterology, vol. 142, no. 1, pp. 46–54, 2012.

[4] M. Salaga, H. Zatorski, M. Sobczak, C. Chen, and J. Fichna, “Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review,” Current Treatment Options in Oncology, vol. 15, no. 3, pp. 405–420, 2014.

[5] S. Rajamanickam and R. Agarwal, “Natural products and colon cancer: current status and future prospects,” Drug Development Research, vol. 69, no. 7, pp. 460–471, 2008.

[6] O. Ginghină, C. Negrei, A. Hudită et al., N. Iordache and A. Balanescu, “In vitro impact of some natural compounds on HT-29 colorectal adenocarcinoma cells,” Farmacia, vol. 65, no. 6, pp. 947–953, 2017.

[7] A. Ahmad, W. A. Sakr, and K. Rahman, “Novel targets for detection of cancer and their modulation by chemopreventive natural compounds,” Frontiers in Bioscience (Elite Ed), vol. 4, pp. 410–425, 2012.

[8] A. Goel, A. B. Kunnunakkara, and B. B. Aggarwal, “Curcumin as “curecumin”: from kitchen to clinic,” Biochemical Pharmacology, vol. 75, no. 4, pp. 787–809, 2008.

[9] Y. Sugiyama, S. Kawakishi, and T. Osawa, “Involvement of the β-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin,” Biochemical Pharmacology, vol. 52, no. 4, pp. 519–525, 1996.

[10] R. Srimal and B. Dhanaw, “Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent,” Journal of Pharmacy and Pharmacology, vol. 25, no. 6, pp. 447–452, 1973.

[11] G. Mahady, S. Pendland, G. Yun, and Z. Lu, “Turmeric (Curcuma longa) and curcumin inhibit the growth of helicobacter pylori, a group 1 carcinogen,” Anticancer Research, vol. 22, no. 6C, pp. 4179–4181, 2002.

[12] S. K. Sandur, M. K. Pandey, B. Sung et al., “Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism,” Carcinogenesis, vol. 28, no. 8, pp. 1765–1773, 2007.

[13] M. Ghandadi and A. Sahebkar, “Curcumin: an effective inhibitor of interleukin-6,” Current Pharmaceutical Design, vol. 23, no. 6, pp. 921–931, 2017.

[14] F. Ghasemi, M. Shafiee, Z. Banikazemi et al., “Curcumin inhibits NF-kB and Wnt/β-catenin pathways in cervical cancer cells,” Pathology Research and Practice, vol. 215, no. 10, Article ID 152556, 2019.

[15] Y. Panahi, N. Khalili, E. Sahebi et al., “Effects of curcinoids plus piperine on glycemic, hepatic and inflammatory biomarkers in patients with type 2 diabetes mellitus: a randomized double-blind placebo-controlled trial,” Drug Research, vol. 68, no. 7, pp. 403–409, 2018.

[16] M. Sadeghian, S. Rahmani, T. Jamialahmadi, T. P. Johnston, and A. Sahebkar, “The effect of oral curcumin supplementation on health-related quality of life: a systematic review and meta-analysis of randomized controlled trials,” Journal of Affective Disorders, vol. 278, pp. 627–636, 2021.

[17] M. Alidadi, T. Jamialahmadi, A. F. G. Cicero et al., “The potential role of plant-derived natural products in improving arterial stiffness: a review of dietary intervention studies,” Journal of Oncology, vol. 9.
Y. Komiya and R. Habas, "Wnt signal transduction pathway," *Molecular Medicine Reports*, vol. 8, no. 1, pp. 282–286, 2013.

Y. Shukla and R. Singh, "Resveratrol and cellular mechanisms of cancer prevention," *Annals of the New York Academy of Sciences*, vol. 1215, no. 1, pp. 1–8, 2011.

A. Y. Berman, R. A. Motechin, M. Y. Wiesenfeld, and M. K. Holz, "The therapeutic potential of resveratrol: a review of clinical trials," *NPJ Precision Oncology*, vol. 1, 2017.

A. Sahebkar, "Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials," *Nutrition Reviews*, vol. 71, no. 12, pp. 822–835, 2013.

A. Sahebkar, C. Serban, S. Ursoniu et al., "Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors—results from a systematic review and meta-analysis of randomized controlled trials," *International Journal of Cardiology*, vol. 189, no. 1, pp. 47–55, 2015.

J. Yao, J. Y. Wang, L. Liu et al., "Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis," *Archives of Medical Research*, vol. 41, no. 4, pp. 288–294, 2010.

C. Alarcon de Lastra and I. Villegas, "Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications," *Molecular Nutrition & Food Research*, vol. 49, no. 5, pp. 405–430, 2005.

P. Zhang, H. Li, B. Yang et al., "Biological significance and therapeutic implication of resveratrol-induced Wnt, notch and STAT3 signaling in cervical cancer cells," *Genes & Cancer*, vol. 5, no. 5–6, p. 154, 2014.

T. Zhan, N. Rindtorff, and M. Boutros, "Wnt signaling in cancer," *Oncogene*, vol. 36, no. 11, pp. 1461–1473, 2017.

P. C. Leow, Q. Tian, Z. Y. Ong, Z. Yang, and P. L. R. Ee, "Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells," *Investigational New Drugs*, vol. 28, no. 6, pp. 766–782, 2010.

W. de Lau, N. Barker, and H. Clevers, "WNT signaling in the normal intestine and colorectal cancer," *Frontiers in Bioscience*, vol. 12, no. 1, pp. 471–491, 2007.

Y. Komiya and R. Habas, "Wnt signal transduction pathways," *Organogenesis*, vol. 4, no. 2, pp. 68–75, 2008.

C. Liu, Y. Li, M. Semenov et al., "Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism," *Cell*, vol. 108, no. 6, pp. 837–847, 2002.

B. T. MacDonald, K. Tamai, and X. He, "Wnt/β-catenin signaling: components, mechanisms, and diseases," *Developmental Cell*, vol. 17, no. 1, pp. 9–26, 2009.

S. G. Pai, B. A. Carneiro, J. M. Mota et al., "Wnt/β-catenin pathway: modulating antitumor immune response," *Journal of Hematology & Oncology*, vol. 10, no. 1, pp. 1–12, 2017.

K. Tamai, X. Zeng, C. Liu et al., "A mechanism for Wnt coreceptor activation," *Molecular Cell*, vol. 13, no. 1, pp. 149–156, 2004.

R. T. Moon, A. D. Kohn, G. V. De Ferrari, and A. Kaykas, "WNT and β-catenin signalling: diseases and therapies," *Nature Reviews Genetics*, vol. 5, no. 9, pp. 691–701, 2004.

P. Polakos, "Wnt signaling in cancer," *Cold Spring Harbor Perspectives in Biology*, vol. 4, no. 5, Article ID a008052, 2012.

L. You, B. He, Z. Xu et al., "An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth," *Cancer Research*, vol. 64, no. 15, pp. 5385–5389, 2004.

Y. S. Park, J. W. Huh, J. H. Lee, and H. R. Kim, "shRNA against CD44 inhibits cell proliferation, invasion and migration, and promotes apoptosis of colon carcinoma cells," *Oncology Reports*, vol. 27, no. 2, pp. 339–346, 2012.

Y. W. Qiang, B. Barlogie, S. Rudikoff, and J. D. Saura, "Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma," *Bone*, vol. 42, no. 4, pp. 669–680, 2008.

N. G. Amado, B. F. Fonseca, D. M. Cerqueira, V. M. Neto, and J. G. Abreu, "Flavonoids: potential Wnt/β-catenin signaling modulators in cancer," *Life Sciences*, vol. 89, no. 15-16, pp. 545–554, 2011.

S. Sell, "On the stem cell origin of cancer," *The American Journal of Pathology*, vol. 176, no. 6, pp. 2584–2594, 2010.

D. Pinto and H. Clevers, "Wnt control of stem cells and differentiation in the intestinal epithelium," *Experimental Cell Research*, vol. 306, no. 2, pp. 357–363, 2005.

B. M. Boman and J. Z. Fields, "An APC: Wnt counter-current-like mechanism regulates cell division along the human colonic crypt axis: a mechanism that explains how APC mutations induce proliferative abnormalities that drive colon cancer development," *Frontiers in Oncology*, vol. 3, p. 244, 2013.

C. G. A. Network, "Comprehensive molecular characterization of human colon and rectal cancer," *Nature*, vol. 487, no. 7407, p. 330, 2012.

S. D. Markowitz and M. M. Bertagnolli, "Molecular basis of colorectal cancer," *New England Journal of Medicine*, vol. 361, no. 25, pp. 2449–2460, 2009.

T. C. He, A. B. Sparks, C. Rago et al., "Identification of c-MYC as a target of the APC pathway," *Science*, vol. 281, no. 5382, pp. 1509–1512, 1998.

O. Tetsu and F. McCormick, "β-catenin regulates expression of cyclin D1 in colon carcinoma cells," *Nature*, vol. 398, no. 6726, pp. 422–426, 1999.

T. Brabletz, A. Jung, S. Dag, F. Hlubek, and T. Kirchner, "β-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer," *The American Journal of Pathology*, vol. 155, no. 4, pp. 1033–1038, 1999.

E. Spears and K. L. Neufeld, "Novel double-negative feedback loop between adenomatous polyposis coli and musashi1 in colon epithelia," *Journal of Biological Chemistry*, vol. 286, no. 7, pp. 4946–4950, 2011.

Y. Zhang, Z. Chen, and J. Li, "The current status of treatment for colorectal cancer in China: a systematic review," *Medicine*, vol. 96, no. 40, 2017.

Y. Li, Z. Liu, X. Guo, and S. Ma, "Overcome multidrug resistance in colorectal cancer by natural compounds," *Science of Advanced Materials*, vol. 12, no. 7, pp. 933–949, 2020.

S. Dihlmann, A. Siermann, and M. von Knebel Doeberitz, "β-catenin/TCF-4 signaling," *Oncogene*, vol. 16, pp. 545–554, 2001.

S. Batra, Y. Shi, K. M. Kuchenbecker et al., "Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma," *Biochemical and Biophysical Research Communications*, vol. 342, no. 4, pp. 1228–1232, 2006.
[54] K. R. Patel, V. A. Brown, D. J. Jones et al., “Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients,” *Cancer Research*, vol. 70, no. 19, pp. 7392–7399, 2010.

[55] R. F. Holcombe, M. Martinez, K. Planutis, and M. Planutiene, “Effects of a grape-supplemented diet on proliferation and Wnt signaling in the colonic mucosa are greatest for those over age 50 and with high arginine consumption,” *Nutrition Journal*, vol. 14, no. 1, pp. 1–8, 2015.

[56] S. Lev-Ari, L. Strier, D. Kazanov et al., “Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells,” *Clinical Cancer Research*, vol. 11, no. 18, pp. 6738–6744, 2005.

[57] B. B. Patel, R. Sengupta, S. Qazi et al., “Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R,” *International Journal of Cancer*, vol. 122, no. 2, pp. 267–273, 2008.

[58] Y. F. Huang, D. J. Zhu, X. W. Chen et al., “Curcumin enhances the effects of irinotecan on colorectal cancer cells through the generation of reactive oxygen species and activation of the endoplasmic reticulum stress pathway,” *Oncotarget*, vol. 8, no. 25, Article ID 40264, 2017.

[59] M. Prici, B. Girardi, F. Giorgio, G. Leosardo, E. Ierardi, and A. di Leo, “Curcumin and colorectal cancer: from basic to clinical evidence,” *International Journal of Molecular Science*, vol. 21, no. 7, 2020.

[60] N. Seiwert, J. Fahrer, G. Nagel, J. Frank, D. Behnam, and J. Okabe, S. Satoh, Y. Furukawa et al., “Involvement of PEG10 in human hepatocellular carcinomaogenesis through interaction with SIAH1,” *Cancer Research*, vol. 63, no. 12, pp. 3043–3048, 2003.

[61] Y. Meng, F. Shang, and Y. Zhu, “MiR-491 functions as a tumor suppressor through Wnt3a/β-catenin signaling in the development of glioma,” *European Review for Medical and Pharmacological Sciences*, vol. 23, no. 24, pp. 10899–10907, 2019.

[62] B. Li, C. Shi, B. Li, J. M. Zhao, and L. Wang, “The effects of curcumin on HCT-116 cells proliferation and apoptosis via the miR-491/PEG10 pathway,” *Journal of Cellular Biochemistry*, vol. 119, no. 4, pp. 3091–3098, 2018.

[63] Z. Mbese, V. Khwaza, and B. A. Adenibigbe, “Curcumin and its derivatives as potential therapeutic agents in prostate, colon and breast cancers,” *Molecules*, vol. 24, no. 23, p. 4386, 2019.

[64] K. Komal, S. Chaudhary, P. Yadav, R. Parmanik, and M. Singh, “The therapeutic and preventive efficacies of curcumin and its derivatives in esophageal cancer,” *Asian Pacific Journal of Cancer Prevention: APJCP*, vol. 20, no. 5, p. 1329, 2019.

[65] M. J. Ryu, M. Cho, J. Y. Song et al., “Natural derivatives of curcumin attenuate the Wnt/β-catenin pathway through down-regulation of the transcriptional coactivator p300,” *Biochemical and Biophysical Research Communications*, vol. 377, no. 4, pp. 1304–1308, 2008.

[66] M. T. Huang, W. Ma, Y. P. Lu et al., “Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrodrcurcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion,” *Carcinogenesis*, vol. 16, no. 10, pp. 2493–2497, 1995.

[67] J. M. Kim, S. Araki, D. J. Kim et al., “Chemopreventive effects of carotenoids and curcumin on mouse colon carcinogenesis after 1, 2-dimethylhydrazine initiation,” *Carcinogenesis*, vol. 19, no. 1, pp. 81–85, 1998.

[68] C. S. Lai, J. C. Wu, S. F. Yu et al., “Tetrahydrocurcumin is more effective than curcumin in preventing aoxymethane-induced colon carcinogenesis,” *Molecular Nutrition & Food Research*, vol. 55, no. 12, pp. 1819–1828, 2011.

[69] W. T. He, Y. H. Zhu, T. Zhang et al., “Curcumin reverses 5-fluorouracil resistance by promoting human colon cancer HCT-8/5-FU cell apoptosis and down-regulating heat shock protein 27 and P-glycoprotein,” *Chinese Journal of Integrative Medicine*, vol. 25, no. 6, pp. 416–424, 2019.

[70] X. Ye, W. L. Tam, T. Shibue et al., “Distinct EMT programs control normal mammary stem cells and tumour-initiating cells,” *Nature*, vol. 525, no. 7568, pp. 256–260, 2015.

[71] Y. Lu, R. Zhang, X. Zhang, B. Zhang, and Q. Yao, “Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress,” *Biomedicine & Pharmacotherapy*, vol. 129, Article ID 110381, 2020.

[72] N. S. Srivastava and R. A. K. Srivastava, “Curcumin and quercetin synergistically inhibit cancer cell proliferation in multiple cancer cells and modulate Wnt/β-catenin signaling and apoptotic pathways in A375 cells,” *Phytomedicine*, vol. 52, pp. 117–128, 2019.

[73] C. DiMarco-Crook and H. Xiao, “Diet-based strategies for cancer chemoprevention: the role of combination regimens using dietary bioactive components,” *Annual Review of Food Science and Technology*, vol. 6, pp. 505–526, 2015.

[74] X. Wu, G. Y. Koh, Y. Huang, J. W. Crott, R. T. Bronson, and J. B. Mason, “The combination of curcumin and salsalate is...
superior to either agent alone in suppressing pro-cancerous molecular pathways and colorectal tumorigenesis in obese mice,” *Molecular Nutrition & Food Research*, vol. 63, no. 8, Article ID 1801079, 2019.

[84] Y. Hu and K. Mombaur, “Analysis of human leg joints compliance in different walking scenarios with an optimal control approach the” research leading to these results has received funding from the European union seventh framework programme (FP7/2007—2013) under grant agreement n. 611909 (Korolbot), “IFAC-Papers on Line, vol. 49, no. 14, pp. 99–106, 2016.

[85] H. Ding, X. Wang, S. Zhang, and X. Liu, “Applications of polymeric micelles with tumor targeted in chemotherapy,” *Journal of Nanoparticle Research*, vol. 14, no. 11, pp. 1–13, 2012.

[86] T. T. Le and D. Kim, “Folate-PEG/Hyd-curcumin/C18-g-PSI micelles for site specific delivery of curcumin to colon cancer cells via Wnt/β-catenin signaling pathway,” *Materials Science and Engineering C*, vol. 101, pp. 464–471, 2019.

[87] X. Jiang, S. Li, X. Qiu, J. Cong, J. Zhou, and W. Miu, “Curcumin inhibits cell viability and increases apoptosis of SW620 human colon adenocarcinoma cells via the caudal type homeobox-2 (CDX2)/Wnt/β-catenin pathway,” *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*, vol. 25, p. 7451, 2019.

[88] A. S. Jaiswal, B. P. Marlow, N. Gupta, and S. Narayan, “β-catenin-mediated transactivation and cell–cell adhesion pathways are important in curcumin (diferulilmethane)-induced growth arrest and apoptosis in colon cancer cells,” *Oncogene*, vol. 21, no. 55, pp. 8414–8427, 2002.

[89] J. Y. Zhu, X. Yang, Y. Chen et al., “Curcumin suppresses lung cancer stem cells via inhibiting Wnt/β-catenin and sonic hedgehog pathways,” *Phytotherapy Research*, vol. 31, no. 4, pp. 680–688, 2017.

[90] S. Mukherjee, M. Mazumdar, S. Chakraborty et al., “Curcumin inhibits breast cancer stem cell migration by amplifying the E-cadherin/β-catenin negative feedback loop,” *Stem Cell Research & Therapy*, vol. 5, no. 5, pp. 1–19, 2014.

[91] P. Su, Y. Yang, G. Wang, X. Chen, and Y. Ju, “Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells,” *International Journal of Oncology*, vol. 53, no. 3, pp. 1343–1353, 2018.

[92] Z. Zhang, H. Chen, C. Xu et al., “Curcumin inhibits tumor epithelial-mesenchymal transition by downregulating the Wnt signaling pathway and upregulating NKD2 expression in colon cancer cells,” *OncoReport*, vol. 35, no. 5, pp. 2615–2623, 2016.

[93] D. Wei, L. Yun, X. Dejun, L. Cong, J. H. He, and L. Yan, “Curcumin combining with si-MALAT1 inhibits the invasion and migration of colon cancer SW480 cells,” *Brazilian Journal of Pharmaceutical Sciences*, vol. 55, 2019.

[94] H. Cao, E. Xu, H. Liu, L. Wan, and M. Lai, “Epithelial–mesenchymal transition in colorectal cancer metastasis: a system review,” *Pathology-Research and Practice*, vol. 211, no. 8, pp. 557–569, 2015.

[95] N. M. Ghaeehari and S. Babashah, “Interplay between microRNAs and WNT/β-catenin signalling pathway regulates epithelial–mesenchymal transition in cancer,” *European Journal of Cancer*, vol. 51, no. 12, pp. 1638–1649, 2015.

[96] V. Schinzari, E. Timperi, G. Pecora et al., “Wnt3a/β-catenin signaling conditions differentiation of partially exhausted T-effector cells in human cancers,” *Cancer Immunology Research*, vol. 6, no. 8, pp. 941–952, 2018.

[97] T. Chen, C. Yang, Z. Xi, F. Chen, and H. Li, “Reduced caudal type homeobox 2 (CDX2) promoter methylation is associated with curcumin’s suppressive effects on epithelial-mesenchymal transition in colorectal cancer cells,” *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*, vol. 26, pp. 0926443–0926441, 2020.

[98] L. Ahmed, P. Chandrakasan, O. Tawfik, L. Xia, S. Anant, and S. Umar, “Critical roles of notch and Wnt/β-catenin pathways in the regulation of hyperplasia and/or colitis in response to bacterial infection,” *Infection and Immunity*, vol. 80, no. 9, pp. 3107–3121, 2012.

[99] C. Hope, K. Planutis, M. Planutiene et al., “Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: implications for colon cancer prevention,” *Molecular Nutrition & Food Research*, vol. 52, no. S1, pp. S52–S61, 2008.

[100] Y. Z. Liu, K. Wu, J. Huang et al., “The PTEN/P13K/Akt and Wnt/β-catenin signaling pathways are involved in the inhibitory effect of resveratrol on human colon cancer cell proliferation,” *International Journal of Oncology*, vol. 45, no. 1, pp. 104–112, 2014.

[101] H. J. Chen, L. S. Hsu, Y. T. Shia, M. W. Lin, and C. M. Lin, “The β-catenin/TCF complex as a novel target of resveratrol in the Wnt/β-catenin signaling pathway,” *Biochemical Pharmacology*, vol. 84, no. 9, pp. 1143–1153, 2012.

[102] A. V. Nguyen, M. Martinez, M. J. Stamatos et al., “Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer,” *Cancer Management and Research*, vol. 1, pp. 25, 2009.

[103] J. Vanamala, L. Reddivari, S. Radhakrishnan, and C. Tarver, *Research Article Resveratrol Suppresses IGF-1 Induced Human Colon Cancer Cell Proliferation and Elevates Apoptosis via Suppression of IGF-1R/Wnt and Activation of p53 Signaling Pathways BMC Cancer*, vol. 10, p. 238, 2010.

[104] M. Davies, S. Gupta, G. Goldspink, and M. Winslet, “The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence,” *International Journal of Colorectal Disease*, vol. 21, no. 3, pp. 201–208, 2006.

[105] S. H. Song, H. Y. Min, and S. K. Lee, “Suppression of prostaglandin E2-mediated cell proliferation and signal transduction by resveratrol in human colon cancer cells,” *Biomolecules & Therapeutics*, vol. 18, no. 4, pp. 402–410, 2010.

[106] Y. T. Chin, S. H. Yang, T. C. Chang et al., “Mechanisms of dihydrotestosterone action on resveratrol-induced anti-proliferation in breast cancer cells with different ERα status,” *Oncotarget*, vol. 6, no. 34, Article ID 35866, 2015.

[107] H. Y. Lin, M. Sun, H. Y. Tang et al., “Resveratrol causes COX-2 and p53-dependent apoptosis in head and neck squamous cell cancers,” *Journal of Cellular Biochemistry*, vol. 104, no. 6, pp. 2131–2142, 2008.

[108] A. W. Nana, Y. T. Chin, C. Y. Lin et al., “Tetrac down-regulates β-catenin and HMG2A to promote the effect of resveratrol in colon cancer,” *Endocrine-Related Cancer*, vol. 25, no. 3, pp. 279–293, 2018.

[109] J. Vanamala, L. Reddivari, S. Radhakrishnan, and C. Tarver, “Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways,” *BMC Cancer*, vol. 10, no. 1, pp. 1–14, 2010.

[110] J. B. Jeong, J. Lee, and S. H. Lee, “TCF4 is a molecular target of resveratrol in the prevention of colorectal cancer,” *International Journal of Molecular Sciences*, vol. 16, no. 5, pp. 10411–10425, 2015.